Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Univercells S.A.. (10/23/15). "Press Release: Univercells SA Enters Strategic Partnership with Takeda Pharmaceutical Company, Ltd. to Produce Affordable Vaccines for Developing Countries". Gosselies.

Organisations Organisation Univercells S.A.
  Organisation 2 Takeda Ventures Inc. (TVI)
  Group Takeda (Group)
Products Product vaccine technology
  Product 2 vaccine
Index term Index term Univercells–Takeda: investment, 201510 equity investment €3m from Takeda Ventures Inc as part of strategic partnership
Persons Person Bultot, Hugues (Univercells 2013– CEO + Co-Founder)
  Person 2 Castillo, José (Univercells 2013– CTO + Co-Founder before Artelis 201011 President)

Univercells SA, a company that designs single-use cost-efficient bioprocess solutions to lead the next generation in biomanufacturing, today announced it has closed an equity investment of €3M with Takeda Pharmaceutical Company Limited (Takeda) through its strategic venture arm, Takeda Ventures, Inc. The companies will launch a development program to tailor Univercells’ continuous integrated manufacturing methods and integrate them into the Takeda vaccines production platform.

“Partnering with Takeda is a strong sign that we are heading in the right direction. We are excited to collaborate with a pioneering global player focused on helping people above all else,” said Hugues Bultot, CEO of Univercells.

“Equal access to health around the globe is critical and we believe this comes through decentralized production, which is the biggest challenge in this new era of biomanufacturing,” said Jose Castillo, CTO of Univercells.

“Takeda is committed to making its vaccines available to people in need, wherever they may live. Reducing production costs while maintaining the highest levels of quality is an important part of our access strategy and manufacturing science plays a critical role,” said Dr. Rajeev Venkayya, president of Takeda’s Vaccine Business Unit.

••• About Univercells •••

Univercells leverages manufacturing sciences to design single-use bioprocess solutions that change the rules in biomanufacturing. Univercells aims to make biologics available and affordable for all by reinventing the way they are manufactured across the globe. The company creates value for manufacturers and healthcare systems with cost efficiency and local supply while increasing patients’ access to healthcare.

Univercells’ process integration and intensification results in a smaller footprint and unit cost that significantly reduces infrastructure investment and sales price. Its innovative approach breaks barriers to entry and allows clients to develop local bioproduction facilities, including those for biosimilars. These production units are less costly to build and to operate, while offering flexible capabilities, from small to large batches. Univercells can manage all or part of the biomanufacturing project, from design and building of manufacturing facilities to maintenance and supply of API’s bulks.

Univercells was founded in 2013 by an experienced partnership with prior entrepreneurial success. José Castillo, CTO and Hughes Bultot, CEO have more than 15 years of expertise working together in the biotechnology and life sciences sectors.

Media and Analysts Contact

Andrew Lloyd & Associates
Hillary Rock-Archer / Lise Beltzung -
Tel: +44 1273 675 100
US + 1 617 202 4491

Record changed: 2019-11-24


Picture [iito] Plain Stupid Simple 650x80px

More documents for Univercells S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top